2123 POSTER MO19391: an open-label safety study of bevacizumab plus taxane monotherapy or in combination as first-line treatment of patients with locally recurrent or metastatic breast cancer (LR or MBC)
I.E. Smith, L. Biganzoli, H. Cortes-Funes, F. Franke, Y. Mostafa Kamel, J.Y. Pierga, K.I. Pritchard, D. Stroyakovs, C. Thomssen, J. VinholesТом:
5
Рік:
2007
Мова:
english
DOI:
10.1016/s1359-6349(07)70885-6
Файл:
PDF, 57 KB
english, 2007